Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.
An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.
The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...
CAMBRIDGE, MA / ACCESS Newswire / December 15, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...
CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX® (mRNA-1083), the ...
Morning Overview on MSN
CureVac sues Moderna, alleging COVID-19 vaccine patent infringement
German biotech firm CureVac has taken Moderna to court in Delaware, claiming the American drugmaker’s blockbuster Spikevax ...
Moderna's mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results